programmes that will prevent needless suffering in travellers and so help increase international trade and tourism.

MYRON G SCHULTZ

Centres for Disease Control,
US Department of Health and Human Services,
Atlanta, Georgia 30333,
USA

6 Haworth J. Travel and health. World Health 1982;April:3-5.

Preterm rupture of the membranes

In between 6% and 12% of pregnancies1 the fetal membranes rupture spontaneously before labour begins—a condition still (rather unsatisfactorily) called "premature" rupture of the membranes. If the pregnancy is at term labour usually follows or is induced with oxytocin to avoid possible infection. In about 2-3% of pregnancies, however, the membranes rupture before 37 weeks' gestation.2 This condition is best called "preterm" rupture of the membranes3: it occurs in around one-third of all preterm deliveries,2 and its management raises difficult questions.

Usually no cause can be found, but a few cases are due to trauma, hydramnios, or cervical incompetence.4 Normally the tensile strength of the membranes is higher in mid-pregnancy than at term5: some investigators6 have reported an abnormally low collagen content in membranes that rupture spontaneously before term, but others7 have found no such abnormality and suggest that the rupture is due to localised weakness. Infection might be a cause,7 since amnionitis is more frequent8 when the membranes rupture just before labour than when they rupture just after its onset,4 and because preterm rupture of the membranes is more common9 when there is vaginal colonisation with group B streptococci.

Diagnosis9 is usually based on the history, the results of examination with a sterile speculum (not digitally), and possibly testing the pool of liquid in the vagina with nitrates. Urinary incontinence may be distinguished by giving the woman oral phenazopyridine to stain the urine. In the few cases10 in which the diagnosis is still not clear staining of the amniotic fluid by amniocentesis has been suggested,8-10 but the risks include adverse effects of dye on the fetus,11 and most obstetricians would prefer to avoid this investigation.

Management presents the two problems of avoiding infection and minimising the risks of prematurity. A recent study in Oxford showed bacterial colonisation in 41% of neonates after preterm rupture of the membranes, compared with 28% after premature rupture of the membranes at term and 23% of term infants after elective amnionitis.1 Bacterial colonisation correlated poorly, however, with chorioamnionitis. Seven of the 42 preterm infants in this survey died, but only one death was associated with septicemia, the rest being due to complications of prematurity. The authors concluded that the major risk to the neonate in these cases is not infection but preterm delivery. The same conclusion has been reached elsewhere,11-15 and the evidence justifies the current trend towards conservative treatment.16 Furthermore, the risk of amnionitis does not increase with the passage of time after rupture of the membranes15 (at least among preterm pregnancies15). In one American study16 of 188 patients with premature rupture of the membranes treated conservatively there were no neonatal deaths from sepsis—even though 19% of the patients went beyond seven days before labour began. In another study17 of 116 patients with preterm rupture the incidence of amnionitis before labour was 5% and of neonatal sepsis 7%; three babies died from prematurity and one fetal death was associated with infection.

How might the risk of infection be reduced? Prophylactic antibiotics are not helpful.1,219 One of the most dangerous pathogens is the group B beta-haemolytic streptococcus,18 Carriers can be identified by vaginal20 or rectal21 cultures, allowing antibiotic treatment to be directed only at high-risk cases14—though there is no evidence22 that treating the mother prevents infection of the neonate. Another approach is to look for early signs of infection by changes in maternal serum. The concentration of C-reactive protein rises at least 12 hours before other signs of infection appear23 and may therefore warn that prompt delivery is indicated. Serum complement activity is low among patients with preterm rupture of the membranes compared with normal pregnant women (possibly because complement is consumed by subclinical infection),24 but it is not yet known whether very low complement values can accurately predict amnionitis.

Several reports14,15,18 have suggested that respiratory distress syndrome becomes less likely the longer delivery is delayed after the membranes rupture, but other studies18,25,26 have found that rupture of the membranes itself does not accelerate maturation of the lung. There seems no basis9 for fears that giving steroids to stimulate production of surfactant might increase the risk of infection, and a study27 of immunoglobulins in the cord blood has suggested that treatment with steroids does not interfere with the fetal humoral response. Steroids have to be given at least 24 hours before delivery to have any useful effects, and treatment with ritodrine to diminish uterine contractions may delay labour for 24 hours14 despite the presence of ruptured membranes—though there is no evidence that ritodrine is effective for more than 24 hours in these circumstances or that such "tocolytic" treatment alone reduces the incidence of respiratory distress. The effectiveness of treatment with steroids may sometimes be monitored by estimating the lecithin:phosphatidyglycerol content26 of the fluid draining from the vagina (provided contamination with maternal urine is avoided28); otherwise some obstetricians recommend amniocentesis.3,7,17,30 though theoretically this might increase the risk of infection.19 Reports29 that caesarean section increases the risk of respiratory distress have recently been disputed,28 and if delivery of a very premature baby becomes inevitable avoiding a potentially traumatic vaginal delivery30 may increase the infant's chances of survival.

JAMES OWEN DRIFF

Lecturer in Obstetrics and Gynaecology,
Bristol Maternity Hospital,
Bristol BS2 8EG

Ketoconazole

Ketoconazole, one of the newer imidazole antifungal agents, is potentially the most useful derivative to date since it can be given by mouth. In vitro it has a broad spectrum of antifungal activity ranging from Candida species and dermatophytes to systemic pathogenic fungi such as Histoplasma capsulatum. Some moulds, including aspergilli, are inhibited only at high concentrations. Ketoconazole appears to act by inhibiting the conversion of lanosterol into ergosterol in the cell wall, though other mechanisms may also play some part. In man peak serum concentrations of 2.5 mg/l are found two to three hours after administration of a single 200-mg tablet.1 Therapeutic serum concentrations do not usually persist longer than eight hours unless a high dose, over 800 mg, is given. Absorption is enhanced in the presence of acid, but whether or not concurrent administration of antacids inhibits uptake is not yet clear.2 The drug is metabolised in the liver, but peak serum concentrations do not appear to be greatly altered in the presence of liver disease. Ketoconazole penetrates the cerebrospinal fluid and the peritoneal cavity in low concentrations, and less than 13% of the absorbed dose is excreted in the urine.

Ketoconazole has been used most widely in the treatment of superficial mycoses such as dermatophytosis and candidiasis. In the former there is good evidence that ketoconazole is effective; for instance, in one open study the investigators showed that 90% of treated patients were improved, particularly when the infection was confined to hairless skin. Three-quarters of the treated patients relapsed within five months of stopping ketoconazole, however, and the effect of the drug on nail infections was not assessed. Onychomycosis caused by dermatophytes can also be successfully treated, though toenail infections in particular are slow to respond and may be refractory to treatment. In one double-blind comparative study4 of ketoconazole (200 mg) and griseofulvin (250 mg ultramicrosize) clinical remissions were induced in 61% and 39% of treated cases respectively. Up till now most investigators have studied broad groups of dermatophyte infections, and it would be most helpful to substantiate these observations in specific forms of dermatophytosis such as tinea capitis.

The value of ketoconazole in chronic mucocutaneous candidiasis has been established in several studies, including one placebo-controlled trial.5 A substantial proportion of treated patients with chronic mucocutaneous candidiasis achieve complete mycological and clinical remission. In one study six out of 17 patients relapsed with oral infection within 8-4 months of stopping the drug but responded to retreatment.6 These results in an infection such as chronic mucocutaneous candidiasis are encouraging and hold out hope that similar persistent infections will respond as well. Ketoconazole is active against vaginal candidiasis and is likely to prove more acceptable to patients than topical treatment. As even short regimens of topical drugs have proved to be highly effective, however, the comparative merits of ketoconazole need to be carefully assessed.

Few reports have appeared of the use of ketoconazole in the subcutaneous mycoses, though some therapeutic effect has been described in chromomycosis.1 Some of the systemic mycoses, however, particularly certain forms of paracoccidioidomycosis,2 respond dramatically to the drug. Some clinical varieties of coccidioidomycosis and histoplasmosis may also respond.3

As yet the value of ketoconazole cannot be assessed in opportunistic fungal infections such as systemic candidiasis or